新药物,囊性纤维化护理的新挑战
Isabelle Fajac1,2,3, Pierre-Régis Burgel4,2,3, Clémence Martin4,2,3
1Department of Respiratory Medicine and National Cystic Fibrosis Reference Centre, Cochin Hospital, Assistance Publique Hôpitaux de Paris, Paris, France isabelle.fajac@u-paris.fr.
概括
囊性纤维化 (CF) 治疗已经在CFTR调节器方面取得了进展,改善了肺功能和生存率. 然而,CF护理的长期影响和挑战需要进一步研究.
科学领域:
- 医学遗传学 医学遗传学
- 肺部病理学 肺部病理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 囊性纤维化 (CF) 是由CFTR基因变异引起的遗传性疾病,导致多器官疾病.
- 在CF护理的进步包括多学科的方法和新的CFTR调节器疗法.
- CFTR调节器已经显著改善了许多CF患者的临床结果.
研究的目的:
- 审查CFTR调节器对囊性纤维化治疗的革命性影响.
- 突出在调制器时代管理CF的新出现的问题和挑战.
- 讨论当前CFTR调节器的局限性以及未来的研究方向.
主要方法:
- 这是一个复习文章.
- 它综合了关于CFTR调节器及其临床影响的当前知识.
- 它确定了CF管理中的未解答问题和未来的挑战.
主要成果:
- 在符合条件的CF患者中,CFTR调节器提供了实质性的临床益处,并改善了肺功能.
- 长期影响,早期治疗影响和新的CF相关疾病是需要研究的领域.
- 某些CFTR变异对调制剂仍然没有反应,一些并发症没有逆转.
结论:
- CFTR调节器代表了囊性纤维化治疗中的范式转变.
- 解决长期结果,调节器耐药性和不断变化的CF护理需求至关重要.
- 进一步的研究对于优化CF管理和改善患者长期存活率至关重要.
相关概念视频
Cystic Fibrosis: Management
145
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
145
Cystic Fibrosis: Pathogenesis
195
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
195
Drugs Used in Lower Respiratory Disorders: Overview
360
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
360
Chronic Pancreatitis II: Collaborative Care
70
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
70
Drug Delivery: Miscellaneous Routes
329
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
329
Drugs for Treatment of Constipation-Predominant IBS
143
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
143


